IP Library › Granted Patent US 12678458
Granted Patent B2
US 12678458 · App. 18/251,645 · Granted Jul 14, 2026

Antiseptic composition

Inventor: Sadek Baiti (Fougeres, FR)
A61K33/38A61K35/644A61K36/185A61K36/28A61P31/04A61P31/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12678458
App. No.
18/251,645
Granted
Jul 14, 2026
Kind
B2
Abstract

A formulation for use as a drug comprises at least colloidal silver, Sambucus nigra extract, Primulae flos cum calycibus extract and/or Hypericum perforatum extract, and Pelargonium sidoides extract. Preferentially, this formulation is used for prophylaxis and/or for antiviral, antibacterial and antifungal treatment. Even more preferentially, the formulation is an antifungal and antibacterial cream.

Claims (26)

1 . Formulation for use as a drug, comprising:

between 20 and 250 mg of total silver per litre of formulation, distributed as:

i. between 70 and 99.99% by total weight of colloidal silver;

ii. between 0.01 and 30% by total weight of ionic silver;

between 0.3 and 5% by weight of Sambucus nigra extract;

between 1 and 9% by weight of Primulae flos cum calycibus extract and/or Hypericum perforatum extract; and

between 1 and 6% by weight of Pelargonium sidoides extract.

2 . Formulation for use as a drug, according to claim 1 , characterized in that said colloidal silver has a particle size between 0.1 and 30 nanometres.

3 . Formulation for use as a drug according to claim 1 , further comprising:

Echinacea extract, and/or

Propolis and/or

Artemisia extract and/or

Allium sativum extract.

4 . Formulation for use as a drug according to claim 3 , comprising:

Between 0.01 and 8% by weight of the Echinacea extract, and/or

Between 0.01 and 7% by weight of the Propolis , and/or

Between 0.5 and 3% by weight of the Artemisia extract, and/or

Between 0.01 and 10% by weight of the Allium sativum extract.

5 . Formulation for use as a drug according to claim 1 , characterised in that it is in a form suitable for oral, intravenous, subcutaneous, nasal, ophthalmic, auricular, rectal, vaginal, respiratory routes of administration or application on the skin.

6 . Formulation for use as a drug according to claim 5 , characterized in that the route of application on the skin is an ointment, cream, patch or gel.

7 . Formulation for use as a drug according to claim 6 , designed for use for antifungal and antibacterial treatment, by application on the skin as a cream.

8 . Formulation for use as a drug according to claim 6 , designed for use for antifungal treatment, by application on the skin as a cream.

9 . Formulation for use as a drug according to claim 6 , designed for use for antibacterial treatment, by application on the skin as a cream.

10 . Formulation for use as a drug according to claim 1 , designed for use for antiviral, antibacterial and antifungal treatment.

11 . Formulation for use as a drug according to claim 1 , designed for use as an antibiotic.

12 . Formulation for use as a drug according to claim 11 , designed for use in antibiotic-resistant patients.